Injection for treating premature ovarian failure

A technology of premature ovarian failure and injection, which is applied in the field of medicine, can solve problems such as hormone imbalance and breast cancer increase, and achieve the effects of increasing secretion, improving hot flashes and hyperhidrosis, and improving menopausal symptoms

Inactive Publication Date: 2012-09-26
东莞市光华生物科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the domestic treatment of premature ovarian failure in women is mostly based on estrogen supplementation therapy, ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] The therapeutic agents contained in each dose of the injection for treating premature ovarian failure in this embodiment are: flavonoids: 50 mg, Vitb6: 30 mg, glutathione: 1.8 g, Vit c: 8 g, amino acids: 0.4 g, pharmaceutical excipients of the present invention Choose glucose; use medical distilled water to configure a large-capacity injection of 50ml, pharmaceutical knowledge well known to those skilled in the art, pharmaceutical excipients can also be selected from fructose, lactose, ribose, arabinose, One or more combinations of mannitol, xylitol, sorbitol, low molecular dextran, calcium gluconate, calcium phosphate, sodium chloride, for the weight of the pharmaceutical excipients added, those skilled in the art can make reasonable For the selection of the volume of the configured agent, dosages in different volumes can also be made according to the requirements; for the source of flavonoids, those skilled in the art can choose different approaches according to the we...

Embodiment 2

[0014] The therapeutic agent contained in each dose of the injection of this embodiment is: Ginkgo biloba: 40ml, cerebroprotein hydrolyzate: flavonoids: 200mg, Vitb6: 10mg, glutathione: 3.2g, Vit c: 3g, amino acid: 0.8g , The pharmaceutical adjuvant of the present embodiment selects calcium gluconate and sodium chloride for use.

Embodiment 3

[0016] The therapeutic agents contained in each dose of the injection in this embodiment are: flavonoids: 50-200 mg, Vitb6: 10-30 mg, glutathione: 1.8-3.2 g, Vit c: 3-8 g, amino acids: 0.4-0.8 g; The pharmaceutical excipients of this embodiment select xylitol and sodium chloride for use.

[0017] The dose of the injection injection of the present invention is formulated with the normal adult dose, and the doctor can appropriately increase or decrease the dose of the injection according to the patient's constitution and age. curative effect. One of the cases is listed here: the dose of the injection injection of the present invention is formulated with a normal adult dose, and the doctor can appropriately increase or decrease the dose of the injection according to the patient's constitution and age. The product of the present invention has undergone many clinical trials , have achieved varying degrees of good curative effect. Here is one case: Lv, female, 42 years old, menstr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicines, in particular to injection for treating premature ovarian failure. The injection comprises 50 to 200 milligrams of flavone, 10 to 30 milligrams of Vitb6, 1.8 to 3.2 grams of glutathione, and 3 to 8 grams of Vit c. The injection enters human body by injecting, is directly absorbed, can effectively and lastingly activate the functions of ovarian cells, repair special nutritional substances of atrophic ovary, promote female hormone balance, improve climacteric symptoms and particularly improve secretion of female hormone and progestogen, and has a remarkable curative effect; the injection is used for comprehensively conditioning various symptoms caused by female endocrine dyscrasia, and has remarkable effects of improving the immunity of the body, preventing osteoporosis and quickly eliminating the symptoms such as hot flash, hidrosis, insomnia, dysphoria, waist soreness, backache, menstrual disorder, skin stain and lumbar and abdominal obesity; and the injection avoids risks and potential safety hazards caused by estradiol in conventional therapy.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to an injection for treating premature ovarian failure. Background technique [0002] Premature ovarian failure is a disease characterized by amenorrhea, estrogen deficiency, and elevated gonadotropin levels in women before menopause. The incidence rate in the general population is 1%-3%, and it accounts for 4% in women with secondary amenorrhea. -8%. Studies abroad have shown that the incidence rate of this disease is 1%-2% among women before 40 years old, 0.1% among women before 30 years old, and about 0.01% before 20 years old. Premature ovarian failure not only causes amenorrhea, secondary infertility, and low estrogen, but also affects many organs in the body such as nerves, metabolism, cardiovascular and cerebrovascular, and bones, seriously affecting the physical and mental health of patients. The etiology of premature ovarian failure is still unclear, and it may be relate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/06A61P15/08A61K36/254A61K31/4415A61K31/375A61K31/352A61K31/195
Inventor 温家慧
Owner 东莞市光华生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap